Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62.
Endocyte Stock Has Seen a Solid Hike in 2018
Endocyte (ECYT) stock rose from $4.28 at the close of market on December 29, 2017, to $23.60 at the close of market on November 20, 2018.
A Closer Look at Insys Therapeutics’ Performance Year-to-Date
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
Seattle Genetics: Impact of the Cascadian Acquisition
Seattle Genetics acquired clinical-stage biopharmaceutical company Cascadian in March for $614.1 million at $10.0 per share.
Innovative Oncology Pipeline Is a Key Growth Driver for Endocyte
Endocyte (ECYT) is a clinical-stage biopharmaceutical company focused on advancing its two next-generation oncology platforms.
Why Endocyte’s Stock Price Rose 11.4% Yesterday
Today, Endocyte stock is trading at $19.16, which reflects ~1.43% growth from yesterday’s closing price of $18.89. Here’s why.